BioCryst Pharmaceuticals Inc
(STU:BO1)
€
7.362
-0.256 (-3.36%)
Market Cap: 1.52 Bil
Enterprise Value: 1.97 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 71/100 BioCryst Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
Jun 15, 2022 / 04:00PM GMT
Release Date Price:
€8.85
(-2.06%)
Jon Wolleben
JMP Securities LLC - Analyst
Hey, good afternoon, everybody. My name is Jon Wolleben, senior analyst here at JMP Securities. I am pleased to have BioCryst Pharmaceuticals here and CEO Jon Stonehouse joining us. So please enjoy the lunch entertainment, and we'll save some time for questions at the end. But Jon, thanks for coming.
Jon Stonehouse
BioCryst Pharmaceuticals, Inc. - President & CEO
Yeah, thank you for having me.
Questions & Answers
Jon Wolleben
JMP Securities LLC - Analyst
And then BioCryst, it's a company that's been around for quite some time. And you guys have had some great success as of late. For those who may not be familiar, what are you guys working on and what's been working so well recently?
Jon Stonehouse
BioCryst Pharmaceuticals, Inc. - President & CEO
Sure. Before I do that, just a reminder, I'll be making some forward-looking statements. They have risks and the risk factors can be found on our website.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot